Dihexa

Also known as: AngIV analogue

Evidence Tier Cextreme riskadvancednot approved

Preclinical procognitive/synaptogenic compound acting via HGF/c-Met axis. No long-term human safety data.

Not Approved

This substance is not approved by any major regulatory body for human therapeutic use. All information is derived from preclinical research, limited clinical studies, or off-label contexts.

No Human Data

No human exposure data has been identified for this substance. All available evidence comes from animal models or in vitro studies. Safety in humans is completely unknown.

Overview

Dihexa is an AngIV analogue proposed to be procognitive and synaptogenic via the HGF/c-Met axis. It binds HGF and facilitates c-Met receptor engagement, associated with synaptogenesis in preclinical literature. In vitro potency is reported but long-term human safety is not established. High counterfeit risk in the nootropic peptide market.

Research Details

Mechanism of Action

Binds HGF and facilitates c-Met receptor engagement; associated with synaptogenesis in preclinical models.

Study Dose Range

Preclinical; in vitro potency in molar ranges. No established human dosing.

Administration Routes

oral, subcutaneous

Onset / Timeline

Animal cognitive endpoints vary by study design; no clear consumer timeline.

Expected Effects

Preclinical synaptogenesis and cognitive enhancement signals.

Adverse Effects

No long-term human safety data; explicitly flag this gap.

Contraindications

No data.

Interaction Notes

Unknown.

Related Goals

Cognitive & Neuroprotection

Known Interactions

caution with NSI-189

Experimental nootropic stack with limited human data and unclear downside profile.

Available From

No vendors currently listed for this peptide.

Frequently Compared

Semax

ACTH fragment analogue with preclinical neurotrophic signaling and limited clinical stroke/cognition data.

Tier B-C

Selank

Tuftsin analogue peptide with anxiolytic/nootropic research and limited clinical GAD data.

Tier B-C

Humanin

Mitochondrial-derived micropeptide with preclinical cytoprotective and neuroprotective research.

Tier C

Cerebrolysin

Porcine neuropeptide mixture used in some international stroke and cognition programs, but not FDA-approved.

Tier C

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.